An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis

Regulatory Peptides

Volumn 146, Issue 1-3, 2008, Pages 250-259

  Santiago, Olga I ^a   Rivera, Edelmarie ^a   Ferder, Leon ^a   Appleyard, Caroline B ^a  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Angiotensin; DSS; Rat; TNBS

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DEXTRAN SULFATE; DRINKING WATER; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; MYELOPEROXIDASE; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; COLITIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WEIGHT CHANGE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE;

ANIMALIA; RATTUS;

EID: 38149038641     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.10.004     Document Type: Article

References (45)

1. Blumberg R.S., and Strober W. Prospects for research in inflammatory bowel disease. JAMA 285 5 (Feb 7 2001) 643-647
2. Sands B.E. Inflammatory bowel disease: past, present, and future. J Gastroenterol 42 1 (2007) 16-25
3. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004) 1620-1633
4. Dagenais N.J., and Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 25 9 (2005) 1213-1229
5. Yang G., Xi Z.X., Wan Y., and Bi G. Changes in circulating and tissue angiotensin II during acute and chronic stress. Biol Signals 2 (1993) 166-172
6. Suzuki Y., Ruiz-Ortega M., and Egido J. Angiotensin II: a double-edged sword in inflammation. J Nephrol 13 Suppl 3 (2000) S101-S110
7. Inserra F., Romano L.A., de Cavanagh E.M., Ercole L., Ferder L.F., and Gomez R.A. Renal interstitial sclerosis in aging: effects of enalapril and nifedipine. J Am Soc Nephrol 7 5 (1996) 676-680
8. Paizis G., Gilbert R.E., Cooper M.E., Murthi P., Schembri J.M., Wu L.L., Rumble J.R., Kelly D.J., Tikellis C., Cox A., Smallwood R.A., and Angus P. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35 3 (2001) 376-385
9. Toblli J.E., Ferder L., Stella I., De Cavanaugh E.M., Angerosa M., and Inserra F. Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. J Urol 168 4 Pt 1 (2002) 1550-1555
10. Bregonzio C., Armando I., Ando H., Jezova M., Baiardi G., and Saavedra J.M. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. A J Physio Gastrointest Liver Physiol 285 (2003) 414-423
11. Johansson B., Holm M., Ewert S., Casselbrant A., Pettersson A., and Fandriks L. Angiotensin II type 2 receptor-mediated duodenal mucosal alkaline secretion in the rat. Am J Physiol 280 6 (2001) 1254-1260
12. Jaszewski R., Tolia V., Ehrinpreis M.N., Bodzin J.H., Peleman R.R., Korlipara R., and Weinstock J.V. Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis. Gastroenterology 98 8 (1990) 1523-1548
13. Wengrower D., Zannineli G., Pappo O., Latella G., Sestieri M., Villanova A., Faitelson Y., Pines M., and Goldin E. Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1. Inflamm Bowel Dis 10 5 (2004) 536-545
14. Inokuchi Y., Morohashi T., Kawana I., Nagashima Y., kihara M., and Umemura S. Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut 54 (2005) 349-356
15. Criscione L., de Gasparo M., Buhlmayer P., Whitebread S., Ramjoue H.P., and Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 110 2 (1993) 761-771
16. Appleyard C.B., and Wallace J.L. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol. 269 (1995) G119-G125
17. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., and Wallace J.L. Hapten induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 (1989) 795-803
18. Hernandez G.A., and Appleyard C.B. Bacterial load in animal models of acute and chronic 'reactivated' colitis. Digestion 67 (2003) 161-169
19. Kassab S., Garadah T., Abu-Hijleh M., Golbahar J., Senok S., Wazir J., and Gumaa K. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats. J Renin Angiotensin Aldosterone Syst 7 4 (Dec 2006) 206-211
20. Xu W., Song S., Huang Y., and Gong Z. Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats. J Gastroenterol Hepatol 21 8 (Aug 2006) 1250-1256
21. Boughton-Smith N.K., Wallace J.L., and Whittle B.J. Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions 25 (1998) 115-123
22. Smith J.W., and Castro G.A. Relation of peroxidase activity in gut mucosa to inflammation. Am J Physiol 234 1 (1978) 72-79
23. Bradley P.P., Priebat D.A., Christensen R.D., and Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Inves Derm 78 (1982) 206-209
24. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PC and the 2-ddCt method. Methods 25 (2001) 401-408
25. Valasek M.A., and Repa J.J. The power of real-time PCR. Adv Physiol Edu 29 (2005) 151-159
26. Hayama F.H., Motta A.C., Silva A., and Migliari D.A. Liquid-based preparations versus conventional cytology; specimen adequacy and diagnostic agreement in oral lesions. Oral Med Pathol 10 (2005) 115-122
27. Fliser D., Buchholz K., and Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 9 (2004) 1103-1107
28. Bauer J.H., and Reams G.P. The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 155 (1995) 1361-1368
29. Kirk J.K. Angiotensin-II receptor antagonists: their place in therapy. Am Fam Phys 59 11 (1999) 3140-3145
30. Beck P.L., Rosenberg I.M., Xavier R.J., Koh T., Wong J.F., and Podolsky D.K. Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells. Am J Pathol 162 2 (2003) 597-608
31. Fuss I.J., Boirivant M., Lacy B., and Strober W. The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. J Immunol 168 (2002) 900-908
32. Nakamura K., Kitani A., Fuss I., Pedersen A., Harada N., Nawata H., and Strober W. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 172 2 (2004) 834-842
33. Ni J., Chen S.-F., and Hollander D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 39 (1996) 234-241
34. Dieleman L.A., Ridwan B.U., Tennyson G.S., Beagley K.W., Bucy B.P., and Elson C.O. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107 (1994) 1643-1652
35. Sivakumar P.V., Westrich G.M., Kanaly S., Garka K., Born T.L., Derry J.M., and Viney J.L. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 50 6 (2002) 812-820
36. Maerten P., Shen C., Colpaert S., Liu Z., Bullens D.A., van Assche G., Penninckx F., Geboes K., Vanham G., Rutgeerts P., and Ceuppens J.L. Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol 135 2 (2004) 310-317
37. Lindsay J.O., Sandison A., Cohen P., Brennan F.M., and Hodgson H.J. IL-10 gene therapy is therapeutic for dextran sodium sulphate-induced murine colitis. Dig Dis Sci 49 7-8 (2004) 1327-1334
38. Lindsay J., Van Montfrans C., Brennan F., Van Deventer S., Drillenburg P., Hodgson H., Te Velde A., and Sol Rodriguez Pena M. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther 9 24 (2002) 1715-1721
39. Fernandez L., Martinez A., Mendoza J.L., Urcelay E., Fernandez-Arquero M., Garcia-paredes J., Diaz-Rubio M., and de la Concha E.G. Interleukin-10 polymorphisms in Spanish patients with IBD. Inflamm Bowel Dis 11 8 (2005) 739-743
40. Sechi L.A., Valentin J.P., Griffin C.A., and Schambelan M. Autoradiographic characterization of angiotensin II receptor subtypes in rat intestine. Am J Physiol 265 (1993) G21-G27
41. Appleyard C.B., Williams J.L., Hathaway C.A., and Percy W.H. Temporal patterns of colonic blood flow and tissue damage in an animal model of colitis. Dig Dis Sci 44 2 (2002) 431-438
42. Mori M., Stokes K.Y., Vowinkel T., Watanabe N., Elrod J.W., Harris N.R., Lefer D.J., Hibi T., and Granger D.N. Colonic blood flow responses in experimental colitis: time course and underlying mechanisms. Am J Physiol 289 (2005) G1024-G1029
43. Petnehazy T., Cooper D., Stokes K.Y., Russell J., Wood K.C., and Granger D.N. Angiotensin II type 1 receptors and the intestinal microvascular dysfunction induced by ischemia and reperfusion. Am J Physiol 290 (2006) G1203-G1210
44. Hume G.E., Fowler E.V., Lincoln D., Eri R., Templeton D., Florin T.H., Cavanaugh J.A., and Radford-Smith G.L. Angiotensinogen and transforming growth factor beta 1: novel genes in the pathogenesis of Crohn's disease. J Med Genet 43 10 (2006) e51
45. Jahovic N., Ercan F., Gedik N., Yuksel M., Sener G., and Alican I. The effect of angiotensin-converting enzyme inhibitors on experimental colitis in rats. Regul Pept 130 1-2 (2000) 67-74 2005